 ROCKVILLE, MD, Dec. 06, 2020 GLOBE NEWSWIRE -- MacroGenics, Inc. NASDAQ: MGNX, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a single-arm, registrational study of flotetuzumab, an investigational, bispecific CD123 × CD3 DART molecule, in patients with primary induction failure PIF and early relapsed less than six months, or ER6 acute myeloid leukemia AML. The data were presented at the 62nd Annual Meeting of the American Society of Hematology ASH taking place December 5-8, 2020. 